Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity
Earlier studies show that immunotherapy (IT) improves prognosis in acute nonlymphatic leukemia (ANLL), and that ANLL cells probably have tumor-associated antigens, for autologous lymphocytes can react to them. Also, IT seems to immunize against allogeneic ANLL cells, but there is no cross-immunity to autologous ones. Moreover, patients immunized against their ANLL cells have no better prognosis than patients not having lymphocytes reacting to their ANLL cells. It has also been suggested that IT causes nonspecific immunostimulation, but IT patients’ lymphocytes actually react less than those of patients not given IT. The current hypothesis is macrophage activation: Lymphocyte suppression in IT could be explained by suppressor macrophages. Colony-stimulating activity, produced by bone marrow macrophages, decreases during remission in patients not given IT, but not in IT patients. Numerically, blood cells from patients given IT form more colonies than those from patients not given IT. Three of eight patients given IT had more colonies than the upper normal limit.
KeywordsAgar Leukemia Candida Autochthonous
Unable to display preview. Download preview PDF.
- Harris R, Zuhrie A, Read C, Freeman C, Melver JE, Geary CG, Delamore IW, Tooth N (to be published) Randomised trial of immunotherapy alone versus no maintenance treatment in adult AML. In: Terry W (ed) Immunotherapy of cancer. Raven Press, New YorkGoogle Scholar
- 5.Hollinshead AC (1978) Active-specific immunotherapy. Immunotherapy of human cancer. Raven Press, New York, pp 213–232Google Scholar
- 8.Ohno R, Yamada K, Ezaki K (1979) Response of remission lymphocytes to autochthonous leukemic cells, no correlation with the prognosis. Abstr Int Congr Haematol Paris p 165Google Scholar
- 10..Reizenstein P (to be published) BCG plus leukemic cell-therapy of patients with acute myeloid leukemia. In: Terry E (ed) Immunotherapy of cancer: Present status of trials in man. Raven Press, New York, p 25Google Scholar
- 11.Reizenstein P, Miale T (1978) Immunotherapy of acute myeloid leukemia in man. In: Rainer A (ed) Immunotherapy of malignant diseases. Schattauer, Stuttgart New York, pp 441–460Google Scholar
- 12.Reizenstein P, Ogier C, Sjögren A-M (to be published) Immunotherapy versus chemotherapy of AML. Response to PHA, allogeneic lymphocytes and leukemic myeloblasts of remission lymphocytes from leukemic patients. 1979 EORTC plenary meeting. In: Mathe G, Muggia FM (eds) Cancer chemo- and immunopharmacology II. Recent results in cancer research, vol 75. Springer, Berlin Heidelberg New York, pp 29–36CrossRefGoogle Scholar
- 13.Schorlemmer H, Opitz W, Etschenberg E, Haddunger N (1979) Macrophage-mediated cytotoxicity. Abstr Physiol Chem 360:1193Google Scholar
- 16.Zigelbhom I (1979) Deficiency of antibody-dependent cytotoxicity and mitogen-induced cellular cytotoxicity effector cell function in patients with AML in remission. Cancer Res 39:3357–3362Google Scholar